



# PVRI 2025 Rio Annual Congress

29 January - 1 February 2025

## Embracing Heterogeneity

Windsor Convention & Expo Centre, R. Martinho de Mesquita, 129 - Barra da Tijuca Rio de Janeiro - RJ, 20031-204



# Programme overview

**Pre-congress satellite meetings**, Windsor Oceanico, 2nd Floor, Oceania

## Wednesday, 29 January

- 08:00-16:00 Innovative Drug Development Initiative (IDDI) Meeting, [Oceania IX](#)
- 08:00-16:00 Infection in Pulmonary Vascular Disease (iPVD) Consortium Meeting, [Oceania X](#)
- 08:00-12:00 Paediatric & Congenital Heart Disease Task Force Meeting, [Oceania II](#)
- 12:30-18:00 PAH-ICON: International Consortium for Genetic Studies in PAH Meeting, [Oceania II](#)
- 13:30-17:40 Imaging Task Force Meeting, [Oceania III](#)
- 16:00-18:00 High Altitude Task Force Meeting, [Oceania X](#)
- 16:00-18:00 PVRI Board Meeting, [Oceania VIII](#)

**Scientific programme**, Windsor Oceanico, 3rd Floor, Asia

## Thursday, 30 January: Heterogeneity in the presentation of PH

- 08:00-11:05 Session 1: Establishing the framework for the classification and diagnosis of PH worldwide
- 11:05-13:00 Buffet lunch [Windsor Barra, Ground Floor, Barra Restaurant](#)
- 11:05-13:00 Career Catalyst Luncheon (bookable), [Windsor Barra, 2nd Floor, Alhambra & El Pardo](#)
- 13:00-16:00 Session 2: Risk stratification and treatment in the new era of PH therapeutics
- 16:00-18:00 Poster presentations
- 18:00-20:00 Welcome Drinks Reception (open to all), [Windsor Barra, 2nd Floor, Alhambra & El Pardo](#)

## Friday, 31 January: Heterogeneity in the pathobiology of PH

- 08:00-11:10 Session 3: Vascular heterogeneity in chronic lung disease
- 11:10-13:00 Buffet lunch [Windsor Barra, Ground Floor, Barra Restaurant](#)
- 11:10-13:00 Women in PH Luncheon (bookable), [Windsor Barra, 2nd Floor, Alhambra & El Pardo](#)
- 13:00-16:30 Session 4: Heterogeneity in PH associated with heart disease
- 16:30-18:00 Poster presentations
- 19:00-23:59 Gala Dinner & Awards Presentation (bookable), [Windsor Barra, Ground Floor, Louvre](#)

## Saturday, 1 February: Learning from heterogeneity to improve outcomes in PH

- 08:00-11:00 Session 5: The individual exposome and its contribution to PH heterogeneity
- 11:00-12:45 Buffet lunch [Windsor Barra, Ground Floor, Barra Restaurant](#)
- 11:00-12:00 Hot topics from PVRI GoDeep (bookable), [Windsor Oceanico, 3rd Floor, Asia](#)
- 12:00-12:45 Pulmonary Circulation Meeting (closed), [Windsor Oceanico, 2nd Floor, Oceania VIII](#)
- 12:45-13:45 Session 6: Quantifying therapeutic responses
- 13:45-14:15 Refreshment break
- 14:15-16:15 Session 7: Leveraging disease heterogeneity in clinical trial design





## Innovative Drug Development Initiative (IDDI)

### Session 1: Introduction

- 08:00-08:05 Welcome  
Speaker TBC
- 08:05-08:20 PVRI IDDI Introduction and organisational changes  
Luke Howard, Peter Fernandes, Sandeep Sahay & Sylvia Nikkho

### Session 2: New Modalities & Technologies in RHF & PH

Co-chairs: Peter Fernandes, Luke Howard

- 08:20-09:00 **Recent advances with inhalation of drugs in PH**  
Introduction, Nick Hill  
Panel: Discussion & debate on what we have learnt and what is still unknown
- 09:00-09:20 **New Modalities & Technology update**  
Novel Devices in the treatment of PH  
Marc Pritzker & John Scandurra
- 09:20-09:50 **GoDeep**  
GoDeep as a resource for in silico studies with a short scenario run-through  
Werner Seeger & Steve Niederer
- 09:50-10:20 **Advancements in the use of Digital Health Technology in drug development**  
Introduction, Jennifer Goldsack  
Panel: Discussion & debate on the clinical, economic and patient-centric value of digital endpoints in clinical drug development

10:20-10:40 Break

### Session 3: Real World Evidence / Real World Data

Co-chairs: Kellie Morland, Jason Weatherald

- 10:40-10:50 Real World Data Delphi to establish core data for global PH Registries  
Sandeep Sahay
- 10:50-11:05 Scoping review  
Sarah Cohen
- 11:05-11:15 Group discussion

### Session 4: Patient Engagement & Empowerment

- 11:15-11:35 Understanding the patient perspective to advance care  
Matt Granato

### Session 5: Access to Care

- 11:35-11:55 Access to Care Workstream achievement and plan  
Vijay Balasubramanian, Sandeep Sahay
- 11:55-12:05 Group discussion

### Session 6: Challenges of Clinical Trial Design, Conduct & Endpoints

Co-chairs: Harm Jan Bogaard, CQ Deng

- 12:05-12:15 Presentation on the Workstream paper "Clinical trial design, end-points, and emerging therapies in PAH", (Weatherald 2024, ERJ) & the key discussions that led to its development  
Jason Weatherald
- 12:15-12:22 Clinical trial endpoints  
Harm Jan Bogaard
- 12:22-12:30 Insights on clinical trial design from the perspective of industry  
CQ Deng
- 12:30-12:35 Group discussion

12:35-13:35 Lunch break

### Session 7: Lung Transplantation in PH

Chair: Reda Girgis

- 13:35-13:50 Anaesthetic Management of PAH  
Andrea Miltiades
- 13:50-14:05 VA ECMO in PAH  
Lara Schaheen
- 14:05-14:15 Group discussion

### Session 8: Paediatric Clinical Trial Design & Endpoints

Co-chairs: Steve Abman, Sylvia Nikkho

Theme: Heterogeneity in Paediatric PH

- 14:15-14:25 Introduction  
Steven Abman
- 14:25-14:35 Enhancement of drug development in paediatric PAH – extrapolation from available adult data  
Sylvia Nikkho - remote
- 14:35-14:45 Challenges of drug development in bronchopulmonary dysplasia  
Steven Abman & Bernard Thebaud- remote
- 14:45-14:55 Group discussion

### Session 9: PH Group III

Co-chairs: Steve Nathan, Sylvia Nikkho

- 14:55-15:05 Past, present, & future of PVD in COPD  
Gabor Kovacs
- 15:05-15:15 Imaging in PH and chronic lung disease  
Shelsey Johnson
- 15:15-15:25 Group discussion
- 15:25-16:00 Wrap up and final comments

Wednesday  
29 January

Windsor Oceanico,  
2nd Floor, Oceania IX



## Infection in Pulmonary Vascular Disease (iPVD) Consortium Task Force

08:00–08:05 Welcome and opening remarks  
Navneet Dhillon

### Session 1: Current updates on infection associated PVDs

Co-chairs: Navneet Dhillon, Suellen Oliveira

08:05–08:25 Pulmonary vascular complications of tuberculosis: PH and beyond  
Brian Allwood

08:25–08:45 Update on multiple co-morbidities and PVD  
Peter Nyasulu

08:45–09:05 Update on HIV and PVD  
Ana Olga Mocumbi

09:05–09:25 Mechanistic overlap between inflammatory pathways relevant to PH and COVID-19  
Stephen Chan

09:25–09:45 Pathobiology of inflammatory immune cells in schistosoma induced PH  
Rahul Kumar

09:45–10:05 Fungal infections induced PH  
Alexandre Fabro

10:05–10:30 Break

### Session 2: Schistosomiasis associated PVD in Latin America

Co-chairs: Ghazwan Butrous, Vinicio de Jesus Perez

10:30–10:50 Overview of Sch-PAH: case-based presentation of the disease spectrum  
Angela Bandeira

10:50–11:10 Clinical and epidemiological aspects of Sch-PAH in Bahia  
Camila Loureiro

11:10–11:30 Clinical and epidemiological aspects of Sch-PAH in Minas Gerais  
Ricardo Correa

11:30–11:50 Clinical presentation of hepatoesplenic schistosomiasis in Brazil  
Roberto José Carvalho

11:50–12:10 Advances in schistosomiasis basic research: insights from Brazil  
Katia Oliveira

12:10–12:30 Insights from NIH schistosomiasis PAH multicenter study  
Rudolf Oliveira

12:30–13:30 Lunch break

### Panel discussions on schistosomiasis

13:30–14:00 Panel 1: Current challenges in diagnosing schistosomiasis, including biomarker availability and diagnostic tools  
Chair: Brian Graham  
Panel: Angela Bandeira, Camila Rezende, Camila Loureiro

14:00–14:30 Panel 2: Epidemiological and preventive aspects of schistosomiasis in Brazil, including current status, future perspectives, and impact on PH development  
Chair: Ricardo Correa  
Panel: Miriam Tendler, Roberto José Carvalho, Rudolf Oliveira, Angela Bandeira

14:30–15:00 Break

### Session 3: Second hit phenomenon in infection associated PVDs

Co-chairs: Rudolf Oliviera, Brian Graham

15:00–15:20 Air pollution, climate change, infection and PH  
Mona Lichtblau

15:20–15:40 Emerging insights into HIV- and methamphetamine-driven PAH: From mechanisms to management  
Prangthip Charoenpong

15:40–16:00 Microbiome and schistosomiasis  
Suellen Oliveira

Poster viewing and discussion will take place during refreshment breaks.

Wednesday  
29 January

Windsor Oceanico,  
2nd Floor, Oceania X





## Paediatric & Congenital Heart Disease Task Force

### Opportunities for involvement with the Paediatric Task Force

08:00-08:03 Introduction and overview. Future directions for the Paediatric Task Force  
Maria Jesus del Cerro

### Ongoing activities and new opportunities at PVRI

*Chair: Maria Jesus del Cerro*

08:03-08:15 PVRI Pulmonary Hypertension Global Patient Survey (PH GPS)  
Shahin Moledina

08:15-08:23 PVRI Innovative Drug Development Initiative (IDDI)  
Steven Abman

08:23-08:30 PVRI GoDeep Registry  
Megan Griffiths, Anne Hilgendorff

08:30-08:40 Discussion  
All

### Collaboration among international registries

*Co-chairs: Shahin Modelina, Rolf Berger*

08:40-08:55 Collaboration between registries: Let's make it real  
Mary Mullen, Shahin Moledina, Maria del cerro, Rolf Berger

08:55-09:10 What adaptations are needed? Do we need rules?  
Maria Jesus del Cerro, Megan Griffiths

09:10-09:40 Discussion  
All

### I have a research project I want to share

09:40-09:50 Genetics of PH study  
Eric Austin

09:50-10:00 Ongoing research: Genetic variants in pediatric PH across different registries & countries  
Rolf Berger

10:00-10:10 Ongoing research: Boston Children's Hospital  
Mary Mullen

10:10-10:20 Ongoing research in PAH in complex congenital heart disease in Mexico  
Humberto Garcia-Aguilar

---

10:20-10:35 Break

---

Wednesday  
29 January

Windsor Oceanico,  
2nd Floor, Oceania II

### 7th World Symposium summary

*Co-chairs: Rolf Berger, Mary Mullen*

10:35-10:45 Major recommendations & rationale  
Dunbar Ivy

10:45-10:50 Neonatal PH: Disease phenotypes & next steps  
Steven Abman

10:50-11:30 Discussion  
All

### I have a clinical case I want to discuss

*Chair: Usha Krishnan*

11:30-12:00 Two cases to be presented





## Imaging Task Force

### International imaging datasets, analysis methods & clinical impact

13:30-13:40 Introduction  
David Kiely

#### Session 1: International PH imaging data

Co-chair: Khodr Tello, David Kiely

13:40-13:55 PVRI Imaging Task Force: updates and future endeavours  
David Kiely, Andy Swift, Rebecca Vanderpool

13:55-14:10 Integration of imaging into the GoDeep registry: challenges and opportunities  
Khodr Tello

14:10-14:25 Imaging practice in PH experience in South America (TBC)

14:25-14:50 Open discussion on integration of imaging into PVRI GoDeep  
All

- > Summary of the session
- > Focused discussion on integration of data and opportunities
  - > What data to integrate
  - > How to collect, anonymise and store data
  - > Database access and management
  - > Opportunities for large scale analysis and large outcome studies

14:50-15:10 Break

#### Session 2: Current & novel imaging approaches to improve diagnosis & phenotyping

Co-chairs: Raul San Jose Estepar, Sandeep Sahay

15:10-15:25 CT Imaging approaches for phenotyping of patients with PH  
Lilian Meijboom

15:25-15:40 Developments in CT imaging for pulmonary vessels  
Farbod Rahaghi

15:40-16:00 4D Flow in PH: better insights into PH hemodynamics  
Mohammed Elbaz, Ben Freed

16:00-16:15 Questions & roundtable discussion  
All

16:15-16:30 Break

### Session 3: Using microCT & computational/AI approaches to improve our understanding of PVD

Co-chairs: David Kiely, Rebecca Vanderpool

16:30-16:45 Synchrotron-based phase-contrast microcomputed tomography (micro-CT) in pulmonary vascular phenotypes  
Karin Tran Lundmark

16:45-17:00 Emerging computational approaches in imaging for PH  
Pietro Nardelli


17:00-17:15 Clinical applications of AI  
Andy Swift

17:15-17:30 Questions and roundtable discussion  
All

17:30-17:40 Closing remarks  
Rebecca Vanderpool, David Kiely

Wednesday  
29 January

Windsor Oceanico,  
2nd Floor, Oceania III





## PAH-ICON: International Consortium for Genetic Studies in PAH

12:30-12:40 Welcome  
Micheala Aldred, Stefan Gräf

### Invited presentations & panel discussions

Each talk includes 10 minutes of discussion time

12:40-13:20 Keynote: Rare disease landscape in Brazil and Latin America  
Roberto Giugliani

13:20-14:00 Update from ClinGen PAH gene and variant expert panel  
Carrie Welch

14:00-14:40 Update from the TBX4Life initiative  
Eric Austin

14:40-14:50 Break

### Abstract presentations

14:50-15:10 Late onset pulmonary veno-occlusive disease associated with rare heterozygous variants of KDR and EIF2AK4  
Vasile Foris

15:10-15:30 Functional characterization of novel KV1.5 variants in PAH  
Andrea Olschewski

15:30-15:50 Spatial profiling identifies localised changes in gene expression in pulmonary vascular remodeling in the sugen hypoxia rat model  
James Klinger

15:50-16:10 Pathogenic PAH gene variants linked to pulmonary vascular pruning in non-hispanic white COPD gene participants  
Vasile Foris

16:10-16:30 Smaller right ventricular volumes correlate with elevated afterload in unaffected carriers of a pathogenic BMPR2 variant  
Eszter Tóth

16:30-16:45 Break

### Building future PH cohorts

16:45- 18:00

- > Examples and experiences from around the globe
- > PVRI GoDeep's future perspective
- > Core data set: Standardisation & harmonisation of phenotypes
- > Leveraging image data
- > Resources, federation & analysis strategies
- > Global ethics & governance

## High-Altitude Task Force

Wednesday  
29 January

Windsor Oceanico,  
2nd Floor, Oceania X

### Challenges to the pulmonary circulation & beyond at high altitude

Co-chairs: Aastha Mishra, Silvia Ulrich

Each talk includes 10 minutes of discussion time

16:00-16:30 Birth at high altitude – immediate challenges & life-long consequences  
Alexandra Heath

16:30-17:00 The role of the endothelium in acute & chronic pulmonary vascular adaptation to hypoxia  
Wolfgang Kübler

17:00-17:30 Patients diagnosed with pulmonary vascular disease (PAH/CTEPH) at high altitude  
Silvia Ulrich

17:30-18:00 Lowlanders with COPD going to altitude – implication for the right heart & the pulmonary vasculature  
Mona Lichtblau

18:00-18:30 High Altitude Task Force meeting





# Scientific programme speakers



**Steven Abman**  
University of Colorado



**Vineet Agrawal**  
Vanderbilt University  
Medical Center



**Rolf Berger**  
University Medical  
Center Groningen



**Ioana Preston**  
Lahey Clinic



**Sasha Prisco**  
University of Minnesota



**Farbod (Nick)  
Rahaghi**  
Brigham and Women's  
Hospital / Harvard  
Medical School



**Prashant Bobhate**  
Kokilaben Dhirubai  
Ambani Hospital



**Harm Jan Bogaard**  
Amsterdam University  
Medical Centers



**Evan Brittain**  
Vanderbilt University  
Medical Center



**Alex Rothman**  
University of Sheffield



**Soni Savai-  
Pullamsetti**  
Max Planck Institute



**Sandeep Sahay**  
Houston Methodist  
Hospital



**Stephen Chan**  
University of Pittsburgh  
School of Medicine



**Vinicio de Jesus  
Perez**  
Stanford University



**Kara Goss**  
UT Southwestern  
Medical Center



**Catherine Simpson**  
Johns Hopkins  
University



**Natascha Sommer**  
University of Giessen &  
Marburg Lung Center



**Rogério Souza**  
University of Sao Paulo  
Medical School



**Anna Hemnes**  
Vanderbilt University  
Medical Center



**Rachel Hopper**  
Lucile Packard  
Children's Hospital/  
Stanford University  
School of Medicine



**Dunbar Ivy**  
Children's Hospital  
Colorado/University  
of Colorado School of  
Medicine



**Edda  
Spiekerkoetter**  
Stanford University



**Charlotte  
Summers**  
University of  
Cambridge



**Andrew Swift**  
University of Sheffield



**Maria Jesus del  
Cerro Marin**  
Hospital Universitario  
Ramón y Cajal



**David Kiely**  
University of Sheffield



**Gabor Kovacs**  
Medical University of  
Graz



**Caio Tavares**  
Imperial College  
London



**Khodr Tello**  
University Hospital  
Giessen



**Mark Toshner**  
University of  
Cambridge



**Wolfgang Kübler**  
Charité -  
Universitätsmedizin  
Berlin



**Grazyna  
Kwapiszewska**  
Medical University  
Graz & Institute of Lung  
Health



**Tim Lahm**  
National Jewish Health



**Karin Tran-  
Lundmark**  
Skane University  
Hospital & Lund  
University



**Rubin Tuder**  
University of Colorado  
Anschutz Medical  
Campus



**Silvia Ulrich**  
University Hospital  
Zurich



**Charly Lai**  
Indiana University  
School of Medicine




**Allan Lawrie**  
Imperial College  
London



**Susan Majka**  
National Jewish  
Health - University Of  
Colorado



**Rebecca  
Vanderpool**  
The Ohio State  
University



**Nidhy Varghese**  
Texas Children's  
Hospital



**Frances Varian**  
University of Sheffield



**Bradley Maron**  
University of Maryland



**Hiromi Matsubara**  
Okayama Medical  
Center



**Valentina Mercurio**  
Federico II University



**Corey Ventetuolo**  
Brown University



**Sofia Villar**  
University of  
Cambridge



**Jason Weatherald**  
University of Alberta



**Shahin Moledina**  
Great Ormond Street  
Hospital



**Steven Niederer**  
Imperial College  
London



**Rudolf Oliveira**  
Federal University of  
Sao Paulo



**Martin Wilkins**  
Imperial College  
London



**Roham Zamanian**  
Stanford University



**Nayeli Zayas**  
Instituto Nacional de  
Cardiología Ignacio  
Chavez



## SESSION 1: Establishing the framework for the classification & diagnosis of PH worldwide

*Moderators: Katarina Zeder, Lindsay Forbes, Sonja Bartolome*

- 08:00-08:05 PVRI President's welcome  
Anna Hemnes
- 08:05-08:20 PH care in Brazil  
Rogerio Souza
- 08:20-08:35 Classification & diagnosis of PH: Updates from the 7th WSPH  
Gabor Kovacs
- 08:35-08:50 Omics-based & data-driven approaches to early disease diagnosis  
Catherine Simpson
- 08:50-08:57 **The prevalence of PH in sickle cell disease in sub-Saharan Africa: A systematic review & meta-analysis**  
Eric Robbins
- 08:57-09:12 CIPHER & CIPHER-MRI studies for early diagnosis of PH  
Ioana Preston
- 09:12-09:27 Advanced medical imaging & AI in PH diagnosis & classification  
Andy Swift

09:27-09:57 **Refreshment break**

*Moderators: Tatiana Kudryashova, Tim Lahm, Gabor Kovacs*

- 09:57-10:12 Cardiopulmonary exercise testing in the diagnosis & phenotyping of PH patients  
Khodr Tello
- 10:12-10:27 Classification & diagnosis of paediatric PH: Updates from the 7th WSPH  
Dunbar Ivy
- 10:27-10:35 **Global treatment disparities within high- and middle-high income PH centers: A cluster analysis by the PVRI IDDI Access to Care Workstream**  
Franz Rischard
- 10:35-10:50 CTEPH & CTED approach to early diagnosis & treatment  
Mark Toshner
- 10:50-11:05 How pre-clinical models can be used to improve clinical phenotyping & early diagnosis  
Vineet Agrawal

11:05-13:00 **Lunch break, Windsor Barra, Ground Floor, Barra Restaurant**

11:05-13:00 **Career Catalyst Luncheon, Windsor Barra, 2nd Floor, Alhambra & El Pardo**  
Hosts: Jason Weatherald, Laura Opegard, Katarina Zeder and Navneet Singh

## SESSION 2: Risk stratification & treatment in the new era of PH therapeutics

*Moderators: Pilar Escribano Subias, Sue Gue, Sandeep Sahay*

- 13:00-13:15 Developments in risk stratification scores in PH  
Valentina Mercurio
- 13:15-13:30 RV phenotyping in PH risk stratification & treatment  
Tim Lahm
- 13:30-13:45 The impact of novel therapeutics on the treatment algorithm of PH  
Sandeep Sahay
- 13:45-13:52 A monoclonal antibody targeting the ZIP12 transporter attenuates severe experimental PAH  
Stephanie Hopley
- 13:52-14:07 Surgical Interventions, mechanical support, & transplant in end-stage PH  
Nayeli Zayas

14:07-14:37 **Refreshment break**

*Moderators: Corey Ventetuolo, Athiththan Yogeswaran, Horst Olschewski*

- 14:37-14:52 Approach to the treatment of Group 1 PH patients with co-morbidities  
Anna Hemnes
- 14:52-15:07 Risk stratification & treatment of paediatric PH  
Rolf Berger
- 15:07-15:15 Preclinical models support the synergistic potential of seralutinib & sotatercept in treating PAH  
Daniel Bachteler
- 15:15-15:30 Medical & surgical management of CTED & CTEPH  
Hiromi Matsubara
- 15:30-16:00 Panel discussion: Realities & challenges of applying PH guidelines for diagnosis & treatment in LMIC  
*Facilitators: Vinicio de Jesus Perez, Werner Seeger, Ana Mocumbi, Gerald Maarman, Mauricio Orozco Levi*

16:00-18:00 **Poster presentations**

18:00-19:30 **Drinks Reception, Windsor Barra, 2nd Floor, Alhambra & El Pardo**

**Thursday  
30 January**

Windsor Oceanico,  
3rd Floor, Asia





**SESSION 3: Vascular heterogeneity in chronic lung disease**

Moderators: *Grazyna Kwapiszewska, Shelsey Johnson, Susan Majka*

- 08:00-08:05 Introduction  
Grazyna Kwapiszewska
- 08:05-08:20 Clinical aspects of PH heterogeneity in chronic lung disease: Same as PAH or different?  
Corey Ventetuolo
- 08:20-08:35 Translational investigations of PH in fibrotic lung disease models  
Susan Majka

08:35-08:42 **RUPERT SWIFT AWARD LECTURE:** Cluster analysis identifies computed tomography imaging-based phenotypes of PH associated with COPD-PH  
Shelsey Johnson

- 08:42-08:50 Endotyping PH in COPD: possible role of systemic & lung iron status  
Horst Olschewski
- 08:50-09:05 Translational investigations of PH in COPD disease models  
Natascha Sommer
- 09:05-09:20 Panel discussion: Comparison of vascular changes in CLD & PAH

09:20-09:50 Refreshment break

Moderators: *David Kiely, Mona Lichtblau, Raúl San José Estépar*

- 09:50-09:55 Introduction  
David Kiely
- 09:55-10:10 Vasculature in CLD: Imaging insights  
Farbod (Nick) Rahaghi
- 10:10-10:25 Pulmonary vascular heterogeneity: Insights from contemporary pathological approaches  
Rubin Tudor
- 10:25-10:33 Elevated vascular hyaluronan as a therapeutic target in PH associated with lung fibrosis  
Harry Karmouty Quintana

10:33-10:40 **BUTROUS FOUNDATION YOUNG INVESTIGATOR AWARD LECTURE:** Impact of IRG1/Itaconate axis on cardiopulmonary phenotype: linking bone marrow dynamics to inter-organ communication  
Golnaz Hesami

- 10:40-10:55 Vascular changes in paediatric chronic lung disease  
Steven Abman
- 10:55-11:10 Panel discussion: Should we target vascular changes in chronic lung disease?

11:10-13:00 Lunch break, Windsor Barra, Ground Floor, Barra Restaurant

11:10-13:00 **Women in PH Luncheon**, Windsor Barra, 2nd Floor, Alhambra & El Pardo  
Host: Anna Hemnes Speakers: Jill Maron, Karin Tran-Lundmark, Ana Olga Mocumbi

**SESSION 4: Heterogeneity in PH associated with heart disease**

Moderators: *Nidhy Varghese, Gaurav Choudhary, Rebecca Vanderpool*

- 13:00-13:05 Introduction  
Nidhy Varghese
- 13:05-13:20 How do HFrEF & HFpEF affect the pulmonary vasculature & how can we model it?  
Charly Lai
- 13:20-13:35 Congenital heart disease & the pulmonary vasculature  
Shahin Moledina
- 13:35-13:42 PH is highly prevalent in rheumatic heart disease in sub-Saharan Africa: a systematic review & meta-analysis  
Katarina Zeder
- 13:42-13:57 Animal models of heart disease PH  
Wolfgang Kübler
- 13:57-14:05 17β-Estradiol enhances right ventricle angiogenesis & endothelial cell fatty acid oxidation in PAH in a carnitine palmitoyltransferase 1-dependent manner  
Simon Bousseau
- 14:05-14:20 Effect of pre and post-tricuspid shunts on the pulmonary vasculature  
Rachel Hopper

14:20-14:50 Refreshment break

Moderators: *Eszter Tóth, Evan Brittain, Philipp Douschan*

- 14:50-14:55 Introduction  
Eszter Tóth
- 14:55-15:10 How can we study the right ventricle to develop novel therapies?  
Edda Spiekerkoetter
- 15:10-15:17 The role of SMYD2/RUNX2 axis in right ventricular hypertrophy & failure  
Vandna Sapehia
- 15:17-15:32 Advances in imaging RV function in humans & animal models with PH  
Rebecca Vanderpool
- 15:32-15:40 Effects of Dapagliflozin on PH in a rat pulmonary vein banding (PVB) model  
Leonhard Blumrich
- 15:40-15:55 Cellular heterogeneity in RV dysfunction  
Soni Savai-Pullamsetti
- 15:55-16:10 Managing RV dysfunction in resource-limited settings  
Prashant Bobhate
- 16:10-16:30 Panel discussion: Barriers & opportunities for RV-targeted diagnostics & therapeutics

16:30-18:00 Poster presentations

19:00-23:59 **Gala Dinner & Award Presentations**, Windsor Barra, Ground Floor, Louvre

**Friday  
31 January**  
Windsor Oceanico,  
3rd Floor, Asia





## SESSION 5: The individual exposome & its contribution to PH heterogeneity

Moderators: *Lan Zhao, Navneet Dhillon, Harry Karmouty Quintana*

- 08:00-08:15 Drug exposures and PH  
Vinicio de Jesus Perez
- 08:15-08:30 Infectious exposures & pulmonary vascular disease  
Rudolf Oliveira
- 08:30-08:45 High altitude exposure and PH  
Silvia Ulrich
- 08:45-09:00 Early life exposures and pulmonary vascular disease  
Kara Goss
- 09:00-09:15 The Microbiome in PH  
Sasha Prisco

09:15-09:45 Refreshment break

Moderators: *Flavia Navarro, Luke Howard, Rudolf Oliveira*

- 09:45-10:00 Less considered exposures that contribute to PH  
Stephen Chan
- 10:00-10:07 Novel potential connection between lung microbiome dysbiosis & P2X7R/c-IAP2-regulated endothelial survival in schistosomiasis-associated PH  
Suellen Darc Oliveira
- 10:07-10:22 Real world activity and exercise perception in PH patients - MyHeart Counts  
Allan Lawrie
- 10:22-10:37 Insights from All of Us/EHR  
Evan Brittain
- 10:37-10:45 Early recruitment & alternative activation of macrophages initiate pathophysiological changes in pulmonary vasculature upon smoke exposure  
Vinita Sharma
- 10:45-11:00 Exposome as a modifiable factor for PH management  
Bradley Maron

11:00-12:45 Lunch break, Windsor Barra, Ground Floor, Barra Restaurant

11:00-12:00 Hot topics from PVRI GoDeep

Chairs: *Martin Wilkins, Paul Hassoun, Werner Seeger*


- Overview of the GoDeep meta-registry Werner Seeger
- Risk scores beyond group 1 PH – baseline and follow-up Athiththan Yogeswaran
- Survival outcomes and Impact of targeted PAH therapy in PoPH Arun Jose
- PAH-targeted therapies in group 3 PH – PDE5 inhibitor therapy associated with improved survival Khodr Tello
- Male survival disadvantage in PH: independent of etiology, age, disease severity, comorbidities and treatment, but race-dependent Evan Brittain

## SESSION 6: Quantifying therapeutic responses

Moderators: *Patricia Thistlethwaite, Andy Sweatt, Steeve Provencher*

- 12:45-13:00 How should we define disease modification?  
Roham Zamanian
- 13:00-13:15 Developing imaging surrogates of vascular histology to quantify reverse remodeling  
Karin Tran-Lundmark
- 13:15-13:23 CT-based discrimination of CTEPH using deep learning clot vessel radiomics & machine learning  
Pietro Nardelli
- 13:23-13:30 Novel insights from functional respiratory imaging (FRI) analysis in phase 2 INS1009-211 study: Treprostinil palmitil inhalation powder (TPIP) impact on pulmonary vasculature in patients with PH-ILD  
Colin Church

13:30-13:45 **A joint talk with PVRI and PHA USA**  
Patient reported outcomes  
Frances Varian



13:45-14:15 Refreshment break

## SESSION 7: Leveraging disease heterogeneity in clinical trial design

Moderators: *Jane Leopold, Navneet Singh, Roham Zamanian*

- 14:15-14:30 What is a platform trial?  
Charlotte Summers
- 14:30-14:45 Global perspective & digital trials  
Caio Tavares
- 14:45-15:00 Update in paediatric clinical trials  
Maria Jesus del Cerro

**Dragon's Den / Shark Tank**

Dragons/Sharks: *Sonja Bartolome, Ardeshir Ghofrani, Charlotte Summers, Paul Corris*

- 15:00-15:05 Dragon Den introduction Martin Wilkins
- 15:05-15:20 PHoenix trial (rationalising current treatments using implanted devices) Alex Rothman
- 15:20-15:35 Stratosphere Bayesian trial for BMPR2 mutation carriers Sofia Villar
- 15:35-15:50 CRAVE: Canadian Right ventricular AdaptiVE platform trial Jason Weatherald
- 15:50-16:00 Summary Martin Wilkins

16:00-16:15 Building and testing a personal digital twin for PH  
Steve Niederer





## CME Credits



The PVRI 2025 Rio: Embracing Heterogeneity, Rio de Janeiro, Brazil 30/01/2025 - 01/02/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **13.5 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



The European Board for Accreditation in Pneumology (EBAP) has granted PVRI 2025 Rio with **15.5 CME credits, plus an additional 3 CME credits as a Mark of Excellence** in recognition of it being an exceptional event. The total EBAP credits delegates can claim is 18.5.



[pvrinstitute.org](http://pvrinstitute.org)

The PVRI is a Charity registered in England and Wales (No. 1127115) and a Company limited by guarantee (No. 05780068).